Granulomatosis with Polyangiitis

• 

  Subject Areas on Research

  • A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group. 
  • A case of restrictive strabismus secondary to orbital Wegener's granulomatosis. 
  • A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). 
  • A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. 
  • A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. 
  • A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. 
  • ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. 
  • Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. 
  • Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. 
  • Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. 
  • Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. 
  • Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. 
  • Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe). 
  • Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). 
  • Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. 
  • Association of Wegener's granulomatosis with HLA-B8. 
  • Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. 
  • Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Wegener's granulomatosis. 
  • Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. 
  • Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. 
  • Cocaine-induced pseudovasculitis. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Computer assisted tomography of orbital lesions in Wegener's granulomatosis. 
  • Cyclophosphamide treatment of diabetes insipidus in Wegener's granulomatosis. 
  • Cyclosporin A therapy for Wegener's granulomatosis. 
  • Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). 
  • Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide. 
  • Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. 
  • Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. 
  • Granulomatous choroiditis in Wegener granulomatosis. 
  • Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. 
  • Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. 
  • IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. 
  • Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. 
  • Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. 
  • Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. 
  • Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. 
  • Multiple unusual manifestations of Wegener's granulomatosis: breast mass, microangiopathic hemolytic anemia, consumptive coagulopathy, and low erythrocyte sedimentation rate. 
  • Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. 
  • Orbital involvement by Wegener's granulomatosis: imaging findings. 
  • Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. 
  • Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). 
  • Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Single-center experience with renal transplantation in patients with Wegener's granulomatosis. 
  • Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. 
  • Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. 
  • The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. 
  • The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. 
  • The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. 
  • The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. 
  • Wegener granulomatosis: CT and MR findings. 
  • Wegener's granulomatosis involving the breast. Report of three cases and review of the literature. 
  • Wegener's granulomatosis of the uterine cervix: a case report and review of the literature. 
  • Wegener's granulomatosis with cardiac involvement masquerading as Lyme disease. 
  • Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. 
  • Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology